Lin BioScience

Exciting News! 🎉 LBS-007, currently being developed by Lin Bioscience, has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of Acute Myeloid Leukemia (AML). This follows the ODD granted by the FDA in March 2018 for the treatment of Acute Lymphocytic Leukemia (ALL), reaffirming the superior mechanism of action of LBS-007. With this designation, the company will receive various administrative assistance from the FDA and enjoy a seven-year market exclusivity period in the U.S. after LBS-007 is approved for marketing.

We are excited to share that Wollongong Private Hospital is currently recruiting patients for an innovative study featuring our novel drug, LBS-007. This research focuses on a new treatment for relapsed/refractory leukemia, providing much-needed hope for patients facing a challenging diagnosis with limited treatment options

⚠ News alert Belite Bio, Inc, a subsidiary of Lin Bioscience, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 American Depositary Shares of the Company (“ADSs”), each ADS representing one ordinary share of the Company at a purchase price of $38.38 per ADS, and the warrants to purchase up to an aggregate of 651,380 ADSs, which will have an initial exercise price equal to $44.14 per ADS and will be immediately exercisable and expire on the five-year anniversary of the issuance, in a registered direct offering. The closing of the offering is expected to occur on or about April 30, 2024, subject to the satisfaction of customary closing conditions. 📖 Read more at: 👉 Belite Bio News Release: https://lnkd.in/gFY8vZi3 #linbioscience #lbs008 #belitebio

Clinical Trials of LBS-007: In 2023, health authorities in both Australia and Taiwan approved the use of LBS-007 in clinical phase I/II trial for acute myeloid leukemia (AML). The ongoing trial in Australia focuses on the safety, tolerability, and finding optimal dosage of LBS-007. We are optimistic about the potential of LBS-007 as a next-generation, highly effective targeted therapy for AML treatment, offering commitment for improving patient survival. Read more about the LBS-007 clinical trial at： https://lnkd.in/g6yUKTy4 #linbioscience #lbs007 #clinicaltrials #acutemyeloidleukemia #TargetedTherapy

How does our lead compound LBS-007 work? 🧐 LBS-007 is a small molecule drug that inhibits CDC7, a protein crucial for cell cycle regulation. By blocking CDC7, it prevents the activation of MCM2, an important protein responsible for initiation of DNA replication. In cancer cells, this leads to DNA damage accumulation during cell division and ultimately triggers cell death, reducing cancer growth. 📰 Read more at: https://lnkd.in/gMKDfUz8 #LBS007 #Cancer #Inhibitors #DNAreplication #LinBioScience

The Wollongong Private Hospital, Clinical Trials and Research Unit (part of the Ramsay Clinical Trials Network), provides patients with access to cutting-edge medical treatments and practices to advance medical care. This year marks a significant expansion of the Unit with a range of specialties. There has been an increase in hematology clinical trials with leading investigators Prof Peter Presgrave, Dr Gurdeep Parmar and Dr Kylie King. The unit will be participating in three cutting-edge Phase I trials, offering hope to individuals with acute leukemia, multiple myeloma and non-Hodgkin lymphoma, utilising the latest advancements in medical research. - Trial of the safety and tolerability of LBS-007 in patients with relapsed and resistant acute leukaemia’s. - A study of IBI3003 in patients with relapsed or refractory multiple myeloma. - Trial investigating IPH6501 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Clinical Trials and Research Manager, Megan Miller, said she is excited to see the growth of the unit and the expansion of the clinical trials portfolio and specialties. She also shared that the team is passionate about increasing and enabling access to innovative clinical research for all people across Illawarra to change and improve healthcare. Find out more about current clinical trials portfolio and research services via ClinicalTrials.WGP@ramsayhealth.com.au or search Wollongong Private Hospital on the ClinTrial Refer App or website. #clinicaltrials #clinicalresearch #research #medicalresearch #ramsayhealthcare #wollongongprivatehospital #peoplecaringforpeople